Safety and Efficacy of Ultrasound-Enhanced Thrombolysis A Comprehensive Review and Meta-Analysis of Randomized and Nonrandomized Studies
Background and Purpose— Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcrania...
Saved in:
Published in | Stroke (1970) Vol. 41; no. 2; pp. 280 - 287 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
01.02.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and Purpose—
Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA).
Subjects and Methods—
Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD±microspheres (μS), tPA+TCCD±μS, and tPA+low-frequency ultrasound.
Results—
A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%–11.2%); tPA+TCCD, 11.1% (95% CI, 0%–28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%– 61.4%); and tPA alone, 2.9% (95% CI, 0%–8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%– 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%–24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD±μS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70–5.25;
P
=0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44–3.60;
P
=0.67).
Conclusions—
The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials. |
---|---|
AbstractList | Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA).BACKGROUND AND PURPOSEUltrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA).Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD+/-microspheres (microS), tPA+TCCD+/-microS, and tPA+low-frequency ultrasound.SUBJECTS AND METHODSThrough Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD+/-microspheres (microS), tPA+TCCD+/-microS, and tPA+low-frequency ultrasound.A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%-11.2%); tPA+TCCD, 11.1% (95% CI, 0%-28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%- 61.4%); and tPA alone, 2.9% (95% CI, 0%-8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%- 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%-24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD+/-microS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70-5.25; P=0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44-3.60; P=0.67).RESULTSA total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%-11.2%); tPA+TCCD, 11.1% (95% CI, 0%-28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%- 61.4%); and tPA alone, 2.9% (95% CI, 0%-8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%- 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%-24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD+/-microS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70-5.25; P=0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44-3.60; P=0.67).The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials.CONCLUSIONSThe present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials. Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA). Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD+/-microspheres (microS), tPA+TCCD+/-microS, and tPA+low-frequency ultrasound. A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%-11.2%); tPA+TCCD, 11.1% (95% CI, 0%-28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%- 61.4%); and tPA alone, 2.9% (95% CI, 0%-8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%- 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%-24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD+/-microS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70-5.25; P=0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44-3.60; P=0.67). The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials. Background and Purpose— Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA). Subjects and Methods— Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD±microspheres (μS), tPA+TCCD±μS, and tPA+low-frequency ultrasound. Results— A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%–11.2%); tPA+TCCD, 11.1% (95% CI, 0%–28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%– 61.4%); and tPA alone, 2.9% (95% CI, 0%–8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%– 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%–24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD±μS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70–5.25; P =0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44–3.60; P =0.67). Conclusions— The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials. |
Author | Larrue, Vincent Rubiera, Marta Ribo, Marc Sergentanis, Theodoros N. Vadikolias, Konstantinos Alexandrov, Andrei V. Perren, Fabienne Eggers, Jürgen Tsivgoulis, Georgios Molina, Carlos A. Saqqur, Maher |
Author_xml | – sequence: 1 givenname: Georgios surname: Tsivgoulis fullname: Tsivgoulis, Georgios organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 2 givenname: Jürgen surname: Eggers fullname: Eggers, Jürgen organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 3 givenname: Marc surname: Ribo fullname: Ribo, Marc organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 4 givenname: Fabienne surname: Perren fullname: Perren, Fabienne organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 5 givenname: Maher surname: Saqqur fullname: Saqqur, Maher organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 6 givenname: Marta surname: Rubiera fullname: Rubiera, Marta organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 7 givenname: Theodoros N. surname: Sergentanis fullname: Sergentanis, Theodoros N. organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 8 givenname: Konstantinos surname: Vadikolias fullname: Vadikolias, Konstantinos organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 9 givenname: Vincent surname: Larrue fullname: Larrue, Vincent organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 10 givenname: Carlos A. surname: Molina fullname: Molina, Carlos A. organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) – sequence: 11 givenname: Andrei V. surname: Alexandrov fullname: Alexandrov, Andrei V. organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.) |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22368174$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20044531$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kd1LwzAUxYNM3If-ByJ9EZ8689U08W2M6sTBwG3PIU0TVumambQP_e-tbFPwwacLl9853HPPGAxqVxsAbhGcIsTQ43rzvnrLZovZFEExTRghkF6AEUowjSnDfABGEBIRYyrEEIxD-IAQYsKTKzDEEFKaEDQC6VpZ03SRqosos7bUSneRs9G2arwKrq2LOKt3qtamiDY77_a5q7pQhmtwaVUVzM1pTsD2OdvMF_Fy9fI6ny1jTVLUxELkkOuEUGtQkguuNaOUcqgNKliCOe_P1dpoSxBVuWLK5tDkKlWMQKF5Tibg4eh78O6zNaGR-zJoU1WqNq4NMiUUJylCuCfvTmSb700hD77cK9_Jc9YeuD8BKmhVWd-nKsMvhwnjKKU993TktHcheGOlLhvVlK7uX1JWEkH5XYD8KaDfCHksoBfTP-Kz_7-yL1y-iH0 |
CODEN | SJCCA7 |
CitedBy_id | crossref_primary_10_1080_14656566_2017_1309022 crossref_primary_10_1016_j_mayocp_2014_03_001 crossref_primary_10_31728_jnn_2020_00084 crossref_primary_10_1039_D2RA04467F crossref_primary_10_1161_STROKEAHA_120_030960 crossref_primary_10_1586_ern_11_3 crossref_primary_10_1016_j_ejvs_2013_05_019 crossref_primary_10_1002_14651858_CD000514_pub3 crossref_primary_10_1111_jth_12321 crossref_primary_10_1177_2396987321989865 crossref_primary_10_1088_0031_9155_60_18_7403 crossref_primary_10_1186_s13089_018_0099_y crossref_primary_10_3389_fneur_2014_00215 crossref_primary_10_1161_STROKEAHA_116_014181 crossref_primary_10_1002_jcu_21978 crossref_primary_10_3171_2011_10_FOCUS11251 crossref_primary_10_1177_154431671403800302 crossref_primary_10_1111_ijs_12536 crossref_primary_10_1186_s43162_025_00419_8 crossref_primary_10_1016_j_jvir_2010_10_007 crossref_primary_10_1186_1477_7819_12_301 crossref_primary_10_1097_RLI_0000000000000369 crossref_primary_10_1016_j_mtbio_2023_100556 crossref_primary_10_1248_bpb_b16_00702 crossref_primary_10_5692_clinicalneurol_50_547 crossref_primary_10_1007_s11239_012_0850_3 crossref_primary_10_1097_NRL_0b013e318236e041 crossref_primary_10_1038_s41598_020_69202_9 crossref_primary_10_1063_1_4973857 crossref_primary_10_7887_jcns_21_383 crossref_primary_10_1016_j_pcad_2015_03_005 crossref_primary_10_1016_j_jstrokecerebrovasdis_2014_06_018 crossref_primary_10_1007_s11936_015_0373_2 crossref_primary_10_1016_j_ijchv_2014_08_003 crossref_primary_10_1155_2013_629378 crossref_primary_10_1371_journal_pone_0168909 crossref_primary_10_7863_ultra_15_11018 crossref_primary_10_1186_s12883_015_0359_4 crossref_primary_10_3389_fphar_2015_00197 crossref_primary_10_1038_srep16026 crossref_primary_10_1016_S1474_4422_19_30026_2 crossref_primary_10_1007_s11239_010_0483_3 crossref_primary_10_3171_2019_9_FOCUS19624 crossref_primary_10_1586_14737175_2014_934676 crossref_primary_10_1186_s13063_016_1754_x crossref_primary_10_1053_j_tvir_2011_12_002 crossref_primary_10_1111_jon_12026 crossref_primary_10_1007_s12975_014_0332_3 crossref_primary_10_1016_j_neuarg_2012_02_002 crossref_primary_10_1016_j_ajem_2019_03_003 crossref_primary_10_1111_ane_12861 crossref_primary_10_1093_brain_awt201 crossref_primary_10_1016_j_ejvs_2010_11_035 crossref_primary_10_1039_C7RA08971F crossref_primary_10_1080_10717544_2021_1879315 crossref_primary_10_1109_TUFFC_2015_007016 crossref_primary_10_3109_02656736_2012_674621 crossref_primary_10_1056_NEJMct1007370 crossref_primary_10_3109_02656736_2012_678029 crossref_primary_10_1002_jum_16611 crossref_primary_10_1016_j_permed_2012_02_022 crossref_primary_10_1016_j_permed_2012_02_023 crossref_primary_10_15420_ecr_2019_6_1 crossref_primary_10_1159_000365555 crossref_primary_10_1016_j_ultrasmedbio_2014_12_006 crossref_primary_10_3171_2012_10_JNS12449 crossref_primary_10_1016_j_thromres_2015_08_027 crossref_primary_10_1016_j_wneu_2011_05_048 crossref_primary_10_1177_1756286419860652 crossref_primary_10_1371_journal_pone_0152898 crossref_primary_10_3171_2017_11_FOCUS17608 crossref_primary_10_3346_jkms_2018_33_e279 crossref_primary_10_1007_s11670_012_0277_6 crossref_primary_10_3390_brainsci13050840 crossref_primary_10_1109_TUFFC_2015_007268 crossref_primary_10_1007_s11936_012_0176_7 crossref_primary_10_1002_brb3_279 crossref_primary_10_1097_RLI_0000000000000059 crossref_primary_10_1073_pnas_2003569117 crossref_primary_10_1517_17530059_2010_495749 crossref_primary_10_1080_1061186X_2017_1365874 crossref_primary_10_1212_WNL_0b013e31826958d3 crossref_primary_10_1111_j_1552_6569_2011_00632_x crossref_primary_10_1016_j_ijcard_2018_05_101 crossref_primary_10_1111_ijs_12340 crossref_primary_10_1371_journal_pone_0210516 crossref_primary_10_1016_j_otc_2010_08_003 crossref_primary_10_1097_MD_0000000000003615 crossref_primary_10_1007_s11940_012_0214_5 crossref_primary_10_1016_S1773_2247_12_50065_1 crossref_primary_10_3892_ol_2015_3509 crossref_primary_10_1038_jcbfm_2011_127 crossref_primary_10_1111_j_1538_7836_2011_04371_x crossref_primary_10_2214_AJR_14_13632 crossref_primary_10_1586_14779072_2015_1075882 crossref_primary_10_1186_1745_6215_12_20 crossref_primary_10_1016_j_ultrasmedbio_2016_03_027 crossref_primary_10_1088_0031_9155_57_15_4951 crossref_primary_10_1161_STROKEAHA_116_014644 crossref_primary_10_1371_journal_pone_0177786 crossref_primary_10_1038_nrneurol_2011_89 crossref_primary_10_3171_2017_11_FOCUS17586 crossref_primary_10_1016_j_eururo_2012_02_019 crossref_primary_10_1016_j_wem_2010_10_007 crossref_primary_10_1586_erc_12_35 crossref_primary_10_1021_acs_bioconjchem_9b00653 crossref_primary_10_31728_jnn_2019_00046 crossref_primary_10_1586_erd_12_88 crossref_primary_10_1080_14712598_2016_1227779 crossref_primary_10_1016_j_permed_2012_02_038 crossref_primary_10_1016_j_fmc_2016_04_005 crossref_primary_10_1155_2017_7021929 crossref_primary_10_1177_2040622310394032 crossref_primary_10_1016_j_emc_2016_06_009 crossref_primary_10_1002_jmri_24451 crossref_primary_10_1007_s15005_019_0068_4 crossref_primary_10_1161_JAHA_115_002716 crossref_primary_10_1016_j_ultrasmedbio_2021_08_017 crossref_primary_10_1016_j_cult_2011_12_008 crossref_primary_10_1016_j_jocn_2018_10_001 crossref_primary_10_7863_ultra_32_7_1117 crossref_primary_10_1177_154431671503900402 crossref_primary_10_1186_s13231_014_0014_y crossref_primary_10_1088_0031_9155_60_19_7695 crossref_primary_10_1007_s12975_011_0080_6 crossref_primary_10_1016_j_brs_2011_03_007 crossref_primary_10_1007_s11051_025_06282_6 crossref_primary_10_1109_TUFFC_2013_2615 |
Cites_doi | 10.1161/strokeaha.107.505594 10.1056/NEJMoa041175 10.1161/01.str.0000199064.94588.39 10.1161/STROKEAHA.108.530931 10.1111/j.1552-6569.2004.tb00226.x 10.1016/j.ultras.2007.11.008 10.1002/9780470773666 10.1016/0041-624X(91)90030-C 10.1161/01.str.0000140890.86779.79 10.1161/01.str.0000221813.27519.0b 10.1136/bmj.327.7414.560 10.1161/circ.98.10.1030 10.1161/strokeaha.107.503870 10.1016/j.ultrasmedbio.2005.03.008 10.1161/str.19.5.3363593 10.1161/01.STR.0000254524.23708.c9 10.1161/01.str.0000258112.14918.24 10.1182/blood.V81.10.2636.2636 10.1002/ana.21723 10.1016/0301-5629(94)00119-X 10.1161/strokeaha.107.505727 10.1161/01.str.0000170707.86793.1a 10.1002/ana.10590 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS |
Copyright_xml | – notice: 2015 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1161/STROKEAHA.109.563304 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4628 |
EndPage | 287 |
ExternalDocumentID | 20044531 22368174 10_1161_STROKEAHA_109_563304 |
Genre | Meta-Analysis Journal Article Review |
GroupedDBID | --- .3C .55 .GJ .XZ .Z2 01R 0R~ 123 1J1 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5RE 5VS 6PF 71W 77Y 7O~ A9M AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AAQQT AARTV AASCR AASOK AAUEB AAXQO AAYEP AAYJJ AAYXX ABASU ABBUW ABDIG ABJNI ABPXF ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACDOF ACEWG ACGFS ACGOD ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADFPA ADGGA ADGHP ADHPY ADNKB AE3 AE6 AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC AYCSE BAWUL BCGUY BOYCO BQLVK BS7 C45 CITATION CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B M18 N4W N9A N~7 N~B N~M O9- OAG OAH OB3 OCUKA ODA ODMTH OGROG OHYEH OK1 OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ R58 RAH RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M W8F WH7 WOQ WOW X3V X3W X7M XXN XYM YFH YHZ YQJ YYP ZB8 ZGI ZZMQN IQODW ACIJW CGR CUY CVF ECM EIF NPM YCJ 7X8 |
ID | FETCH-LOGICAL-c371t-99b08c534fe15b98cc644480ce1d65288152ccecf314aba6afb0eba7a6309c8b3 |
ISSN | 0039-2499 1524-4628 |
IngestDate | Fri Jul 11 10:27:08 EDT 2025 Thu Apr 03 06:56:22 EDT 2025 Mon Jul 21 09:13:57 EDT 2025 Tue Jul 01 03:03:47 EDT 2025 Thu Apr 24 23:08:52 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Doppler ultrasound study sonothrombolysis Stroke Nervous system diseases Serine endopeptidases tissue plasminogen activator Enzyme Color Cardiovascular disease t-Plasminogen activator Cerebral disorder Vascular disease transcranial color-coded duplex Peptidases transcranial Doppler Central nervous system disease Hydrolases Ultrasound ultrasound-enhancedthrombolysis Cerebrovascular disease |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c371t-99b08c534fe15b98cc644480ce1d65288152ccecf314aba6afb0eba7a6309c8b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
PMID | 20044531 |
PQID | 734257112 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_734257112 pubmed_primary_20044531 pascalfrancis_primary_22368174 crossref_citationtrail_10_1161_STROKEAHA_109_563304 crossref_primary_10_1161_STROKEAHA_109_563304 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-02-01 |
PublicationDateYYYYMMDD | 2010-02-01 |
PublicationDate_xml | – month: 02 year: 2010 text: 2010-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Stroke (1970) |
PublicationTitleAlternate | Stroke |
PublicationYear | 2010 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 (e_1_3_2_20_2) 2006; 1 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_1_2 (e_1_3_2_9_2) 2008; 25 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 (e_1_3_2_14_2) 1986; 17 (e_1_3_2_10_2) 2007; 38 |
References_xml | – ident: e_1_3_2_3_2 doi: 10.1161/strokeaha.107.505594 – ident: e_1_3_2_5_2 doi: 10.1056/NEJMoa041175 – ident: e_1_3_2_6_2 doi: 10.1161/01.str.0000199064.94588.39 – ident: e_1_3_2_1_2 doi: 10.1161/STROKEAHA.108.530931 – ident: e_1_3_2_4_2 doi: 10.1111/j.1552-6569.2004.tb00226.x – ident: e_1_3_2_2_2 doi: 10.1016/j.ultras.2007.11.008 – volume: 25 start-page: 19 year: 2008 ident: e_1_3_2_9_2 publication-title: J Thromb Thrombolysis – ident: e_1_3_2_21_2 doi: 10.1002/9780470773666 – ident: e_1_3_2_13_2 doi: 10.1016/0041-624X(91)90030-C – ident: e_1_3_2_16_2 doi: 10.1161/01.str.0000140890.86779.79 – volume: 1 start-page: 136 year: 2006 ident: e_1_3_2_20_2 publication-title: J Usability Studies – ident: e_1_3_2_27_2 doi: 10.1161/01.str.0000221813.27519.0b – ident: e_1_3_2_22_2 doi: 10.1136/bmj.327.7414.560 – ident: e_1_3_2_24_2 doi: 10.1161/circ.98.10.1030 – ident: e_1_3_2_11_2 doi: 10.1161/strokeaha.107.503870 – ident: e_1_3_2_15_2 doi: 10.1016/j.ultrasmedbio.2005.03.008 – ident: e_1_3_2_19_2 doi: 10.1161/str.19.5.3363593 – ident: e_1_3_2_17_2 doi: 10.1161/01.STR.0000254524.23708.c9 – ident: e_1_3_2_18_2 doi: 10.1161/01.str.0000258112.14918.24 – volume: 38 start-page: 472. year: 2007 ident: e_1_3_2_10_2 publication-title: Stroke – ident: e_1_3_2_26_2 doi: 10.1182/blood.V81.10.2636.2636 – ident: e_1_3_2_23_2 doi: 10.1002/ana.21723 – ident: e_1_3_2_25_2 doi: 10.1016/0301-5629(94)00119-X – ident: e_1_3_2_7_2 doi: 10.1161/strokeaha.107.505727 – ident: e_1_3_2_12_2 doi: 10.1161/01.str.0000170707.86793.1a – volume: 17 start-page: 95 year: 1986 ident: e_1_3_2_14_2 publication-title: Cardiovasc Clin – ident: e_1_3_2_8_2 doi: 10.1002/ana.10590 |
SSID | ssj0002385 |
Score | 2.3994842 |
SecondaryResourceType | review_article |
Snippet | Background and Purpose—
Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3... Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 280 |
SubjectTerms | Aged Aged, 80 and over Biological and medical sciences Brain Ischemia - diagnostic imaging Brain Ischemia - physiopathology Brain Ischemia - therapy Cardiovascular system Combined Modality Therapy - adverse effects Combined Modality Therapy - methods Combined Modality Therapy - statistics & numerical data Female Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - adverse effects Humans Intracranial Thrombosis - diagnostic imaging Intracranial Thrombosis - physiopathology Intracranial Thrombosis - therapy Male Medical sciences Middle Aged Neurology Pharmacology. Drug treatments Randomized Controlled Trials as Topic - statistics & numerical data Thrombolytic Therapy - adverse effects Thrombolytic Therapy - methods Thrombolytic Therapy - statistics & numerical data Tissue Plasminogen Activator - administration & dosage Tissue Plasminogen Activator - adverse effects Treatment Outcome Ultrasonic Therapy - adverse effects Ultrasonic Therapy - methods Ultrasonic Therapy - statistics & numerical data Ultrasonography, Doppler, Transcranial - adverse effects Ultrasonography, Doppler, Transcranial - methods Ultrasonography, Doppler, Transcranial - statistics & numerical data Vascular diseases and vascular malformations of the nervous system Vasodilator agents. Cerebral vasodilators |
Subtitle | A Comprehensive Review and Meta-Analysis of Randomized and Nonrandomized Studies |
Title | Safety and Efficacy of Ultrasound-Enhanced Thrombolysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20044531 https://www.proquest.com/docview/734257112 |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BkRASQrwJj8oHenTwY3dtH6MoVdSqIEgi9WbtrnfTqCWuHIcDv54Z78Z2ITzKxbIs78r2jL95zxDy3pgwUgVjPpdM-1RL6mdMR76JmQRsFCYrsN757COfLujJOTvvvEpNdUkth-r73rqS_6EqXAO6YpXsLSjbbgoX4BzoC0egMBz_icYzYTDjEn3fE2wFgaPbQflbXNWV2OC8JH-yvrAh_vlFVX6VZdOApK-QzuqqvGz0zDBLgp5fYL5ZfVu249Ib1_mq7BTw5dINVzvZHo3HR2mKRZxt9GYlS1cIpDrsrSoLccdCNllmfYcDxsrb5A0HojEGZexco6F2uBlRH8tc-8BKwx4DRX2UtMObnMCNrMT9Fcs5Yvls_uXT6WQ0HWHjqyHj6H_pZNcuXv-TSGsTDRsTh4d5uwtG3HO7y11yLwLbAsdenH7uWsyDDmPHXri3dPWWsMuHfc9yQ595eC028GsZOxPl90ZLo7zMH5NHzurwRpaFnpA7ev2U3D9zeRXPSGI5yQNO8nac5JXG28NJXp-TnpPF8WQ-nvpupIav4iSs_SyTQapYTI0OmcxSpUAfpmmgdFhwFqUpEFIprUwcUiEFF0YGWopE8DjIVCrjF-RgXa71K-JJZhgvBKdBgQ2SYlBzAqp4YSiTCQD7gMS7D5Mr128ex55c5X8iyoD47apr22_lL_cf3vjm7SJQe3kK5vaAeDsi5ICcGA4Ta11uN3kSo7wCe2NAXlridIsxzwGk0-tbPs0b8qD7Y96Sg7ra6negtNbysGGyH6WLjnw |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+Efficacy+of+Ultrasound-Enhanced+Thrombolysis&rft.jtitle=Stroke+%281970%29&rft.au=Tsivgoulis%2C+Georgios&rft.au=Eggers%2C+Ju%CC%88rgen&rft.au=Ribo%2C+Marc&rft.au=Perren%2C+Fabienne&rft.date=2010-02-01&rft.issn=0039-2499&rft.eissn=1524-4628&rft.volume=41&rft.issue=2&rft.spage=280&rft.epage=287&rft_id=info:doi/10.1161%2FSTROKEAHA.109.563304&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_STROKEAHA_109_563304 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0039-2499&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0039-2499&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0039-2499&client=summon |